These studies were designed to investigate the protective effects of the new
angiotensin II receptors antagonist
BAY 10-6734 (6-n-butyl-4-methoxycarbonyl-2-oxo-1[(2'-(1H-tetrazol-5-yl) -3-fluorobiphenyl-4-yl)methyl] 1,2-
dihydropyridine, CAS 156001-18-2) on haemodynamic, hormonal, renal, and structural parameters in
renin transgenic rats (TGR(mRen2)27),
salt-loaded Dahl S and R rats, and
salt-loaded
stroke-prone spontaneously hypertensive rats (SHR-SP) in long-term trials. Study 1: In SHR-SP the development of blood pressure,
cardiac hypertrophy, and the deleterious effects of
salt loading on kidney structure and kidney function was prevented by
BAY 10-6734. Study 2: In
salt-loaded Dahl S rats with a suppressed plasma
renin activity treatment with
BAY 10-6734 did not delay the increase in blood pressure but prevented
cardiac hypertrophy and the increase in plasma
ANP (
Atrial natriuretic peptide). Study 3: TGR develop
malignant hypertension associated with
cardiac hypertrophy, elevated left-ventricular end-diastolic pressure and increased plasma
ANP. After 6 weeks of treatment with
BAY 10-6734 (30 mg/kg p.o. bid) cardiac pump function was improved and
cardiac hypertrophy was reversed in this angiotension dependent form of
hypertension. The beneficial effects of
BAY 10-6734 in these different animal
hypertension models are also emphasized by a reduction in mortality.